Maternal Cytomegalovirus Infection and Congenital Cytomegalovirus Disease: Laboratory Diagnosis, Antiviral Therapy, and Maternal–Pediatric Management
Saudi Journal of Medicine and Public Health · 15.11.2026 · 3 (1) · 486-497
DOI: 10.64483/202631854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Saudi Journal of Medicine and Public Health, online erschienen am 15.11.2026. Verfasst von Abdullah Mohammed Haef Alotaibi und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Congenital cytomegalovirus (CMV) infection is the most common congenital viral infection and a major cause of sensorineural hearing loss and neurodevelopmental impairment in children. Maternal infection frequently remains undiagnosed because most women are asymptomatic or present with nonspecific manifestations.
Aim
This review examines the epidemiology, virology, pathogenesis, maternal risk factors, diagnostic approaches, preventive strategies, and clinical management of congenital CMV infection.
Methods
Relevant literature was reviewed to summarize current evidence on maternal primary and non-primary infections, viral latency, placental transmission, serological and molecular diagnosis, secondary prevention, neonatal assessment, antiviral treatment, and emerging vaccine strategies.
Results
Maternal primary and non-primary infections can result in fetal transmission, although the risk varies according to infection type and timing. Diagnosis remains challenging because of the limitations of maternal serological and molecular tests. Neonatal CMV PCR testing using urine or saliva collected within the first three weeks of life remains the diagnostic standard. High-dose valaciclovir may reduce fetal transmission following early maternal primary infection, while valganciclovir is recommended for selected symptomatic newborns, particularly those with central nervous system involvement. Long-term audiological and neurodevelopmental follow-up is necessary because complications may develop after birth, even in initially asymptomatic infants. Vaccine development remains challenging, and no licensed CMV vaccine is currently available.
Conclusion
Early maternal screening, accurate diagnosis, evidence-based preventive interventions, and appropriate neonatal management are essential to reduce the burden of congenital CMV infection. Further research should focus on improving diagnostic methods, understanding protective maternal immunity, and developing effective vaccines.
Zitieren
APA
Alotaibi, A. M. H., Alotaibi, S. A., Alotaibi, M. A., Darraj, M. A., Alotaibi, N. M. M., Alzahrani, A. H. A., Alsulami, A. O., Alshehri, M. S., Albalawi, A. S., & Aljohani, M. S. (2026). Maternal Cytomegalovirus Infection and Congenital Cytomegalovirus Disease: Laboratory Diagnosis, Antiviral Therapy, and Maternal–Pediatric Management. Saudi Journal of Medicine and Public Health, 3(1), 486-497. https://doi.org/10.64483/202631854
Vancouver
Alotaibi AMH, Alotaibi SA, Alotaibi MA, Darraj MA, Alotaibi NMM, Alzahrani AHA, et al. Maternal Cytomegalovirus Infection and Congenital Cytomegalovirus Disease: Laboratory Diagnosis, Antiviral Therapy, and Maternal–Pediatric Management. Saudi Journal of Medicine and Public Health. 2026;3(1):486-497. doi:10.64483/202631854
BibTeX
@article{Alotaibi2026,
author = {Alotaibi, Abdullah Mohammed Haef and Alotaibi, Salman Abdulrahman and Alotaibi, Muneera Abdulrhman and Darraj, Mohammed Ahmed and Alotaibi, Norah Mania Mutlag and Alzahrani, Alaa Hayas Abdullah and Alsulami, Ahlam Omran and Alshehri, Majed Shar and Albalawi, Areej Saud and Aljohani, Maram Saad},
title = {Maternal Cytomegalovirus Infection and Congenital Cytomegalovirus Disease: Laboratory Diagnosis, Antiviral Therapy, and Maternal–Pediatric Management},
journal = {Saudi Journal of Medicine and Public Health},
year = {2026},
volume = {3},
number = {1},
pages = {486--497},
doi = {10.64483/202631854}
}
EUVIMED